PUBLICATIONS GAVIN MARX


Kate Mahon, Hui-Ming Lin, Lesley Castillo, Brian Lee, Michelle Lee-Ng, Mark Chatfield, Karen Chiam, Samuel Breit, David Brown, Gavin Marx, Mark Molloy, Nick Pavlakis, Michael Boyer, Martin R Stockler, Roger J Daly, Susan Henshall, and Lisa Horvath. Cytokine profiling of docetaxel-resistant castration resistant prostate cancer. *BJC* 2015


M. Khasraw¹, N. Pavlakis¹, S. McCowatt¹,², C. Underhill³, S. Begbie⁴, P. de Souza⁵, A. Boyce⁶, F. Parnis⁷, V. Lim¹, R Harvie¹ and **G Marx**. Multicentre Phase I/II Study of PI-88, a Heparanase Inhibitor in Combination with Docetaxel in Patients with Metastatic Castrate-Resistant Prostate Cancer. *Annals of Oncology. Nov 2009*

Liangli Zhao¹, Brian Y. Lee¹, David A. Brown³, Mark P. Molloy⁴, **Gavin M. Marx**⁵, Nick Pavlakis⁵, Michael J. Boyer⁶, Martin R. Stockler⁶, Warren Kaplan², Samuel N. Breit³, Robert L. Sutherland¹, Susan M. Henshall¹ and Lisa G. Horvath. Identification of Candidate Biomarkers of Therapeutic Response to Docetaxel by Proteomic Profiling. *Cancer Research 69, 7696, October 1, 2009*


Elizabeth Hovey¹, **Gavin Marx**², Andrew Kneebone³, Manish Patel⁴ and Jeremy Shapiro An Australian Clinical Perspective: Management of Hormone Refractory (Androgen-Independent) Prostate Cancer. *Asia Pacific Journal of Oncology and Haematology 2009*

**Gavin M. Marx**, Nick Pavlakis, Sally McCowatt, Stephen Begbie, Craig Underhill, Adam Boyce, David Bell, Phillip Katelaris, Rozelle Harvie, Chris Ward. A Phase II Trial of Docetaxel and Thalidomide in Patients with Metastatic Androgen Independent Prostate Cancer. The ProTaT Trial. *Manuscript in preparation*

Rozelle Harvie MSc ¹,², Florian Paturi ¹, Robyn Taylor BAppSci ², Ross Davey PhD¹,², Rick Abraham³, **Gavin Marx**², Martin Cullen², Zoltan Kerestes PhD¹,², and Nick Pavlakis¹,². The predictive role of serum VEGF in an advanced malignant mesothelioma (MM) patient cohort treated with thalidomide alone or combined with cisplatin/gemcitabine. *Manuscript in preparation*
M. Khasraw and **Gavin Marx**. Chemotherapy in the elderly.  


*Women’s Oncology Review* 2004; 4: 133-134


Ring A, **Marx G**, Steer C, Prendiville J, Ellis P. Poor uptake of influenza vaccinations in patients receiving cytotoxic chemotherapy.  

Ng T, **Marx G**, Littlewood T, Macdougall I. Recombinant Erythropoietin in clinical practice.  

*Lung Cancer*. 2002 Nov; 38 Suppl 2: S51-4 - Review


Marx G, Goldstein D. Elevated Alpha foetoprotein and hepatic metastases-is not always what it seems! *Annals of Oncology. 2002; 13:167-169*


Ring A, **Marx GM**, Steer CB, Harper PG. Flu vaccination and Chemotherapy. *A cancer centre’s experience (submitted for publication)*

**Marx G** and Goldstein D. Outpatient Treatment with Subcutaneous Interleukin-2, Interferon A and Fluorouracil in Patients With Metastatic Renal Cancer: An Australian Experience. *Manuscript completed for publication.*

**ORAL PRESENTATIONS GAVIN MARX**

Correlating Ki67 and other prognostic markers with Oncotype DX recurrence score in early breast cancer Bob T Li, Suzanne Danieletto, Eva S Fong, Angela E Li, Trevor Currer, Andrew Parasyn, Philip Middleton, Heidi Wong, Denis Smart, Michael Hughes, Josie J Rutovitz, **Gavin M Marx**.

*Clinical Oncological Society of Australia Nov 2012*


E Galani, G M Marx, A Strickland, S Rankin, R Mason, P G Harper. An evaluation of PET, EUS and CT scanning in the staging and response to chemotherapy of patients with oesophageal cancer and correlation with pathology at resection. 
Forum of Clinical Oncology. Abstract 1, page 13912
Pan-hellenic congress of Clinical Oncology. April 2004

ASCO 2000

Abstract MOG Meeting 1999

BOOK CHAPTERS GAVIN MARX


Gavin M. Marx, M.D., Michael L. Friedlander, M.D. Drug toxicity, prevention and management of side effects.
Accepted for publication Gynae Oncology Edited by Peter Bosze

Michelle Harrison MD Gavin M. Marx, M.D., Neville Hacker, M.D. Michael L. Friedlander, M.D. Cytotoxic drug treatment of vulval and vaginal cancer.
Accepted for publication in Gynae Oncology Text Edited by Peter Bosze

ABSTRACTS GAVIN MARX

Kate Lynette Mahon, Hui-Ming Lin, Calan Spielman, Michelle Lee-Ng, Howard Gurney, Girish Mallesara, Martin R. Stockler, Karen P. Briscoe, Gavin M. Marx, Samuel N. Breit, David A. Brown, Lisa Horvath; Phase II trial of circulating cytokines as markers of docetaxel (DTX) resistance in metastatic castrate-resistant prostate cancer (mCRPC).
J Clin Oncol 34, 2016 (suppl; abstr 5039)
Basch EM, Scholz M, de Bono JS, Vogelzang N, de Souza P, Marx G, Vaishampayan U, George S, Schwartz J, Antonarakis ES, O'Sullivan JM, Kalebasty AR, Chi KN, Dreicer R, Hutson TE, Final Analysis of COMET-2: Cabozantinib versus Mitoxantrone/Prednisone in Metastatic Castration-Resistant Prostate Cancer (mCRPC) Patients With Moderate to Severe Pain Who Were Previously Treated With Docetaxel and Abiraterone and/or Enzalutamide. ASCO GU 2015

David Chan, Jennifer Mary McLachlan, Megan Crumbaker, Gavin M. Marx; Royal North Shore Hospital, St. Leonards, Australia; Northern Haematology and Oncology Group, Sydney, Australia. Pre-treatment neutrophil/lymphocyte ratio (NLR) prior to steroids as a prognostic factor in metastatic castrate refractory prostate cancer (mCRPC) patients treated with taxanes.

J Clin Oncol 33, 2015 (suppl 7; abstr 273) ASCO GU 2015

Donald Patrick, Charles S. Cleeland, Lesley Fallowfield, Matthew Raymond Smith, Laurence Klotz, Stephane Oudard, Gavin M. Marx, Rachel Wei, Katarina Ohrling, Yi Qian. Denosumab or zoledronic acid (ZA) therapy on pain interference and cancer-specific quality of life (CSQoL) in patients with castrate-resistant prostate cancer (CRPC) and bone metastases (BM).

J Clin Oncol 32, 2014 (suppl 4; abstr 12) ASCO GU 2014

Kate Lynette Mahon, Wenjia Qu, James Devaney, Cheryl Paul, Lesley Castillo, Richard Wykes, Mark D Chatfield, Michael J. Boyer, Martin R. Stockler, Gavin M. Marx, Howard Gurney, Girish Mallesara Hiriyanna Gowda, Peter Molloy, Lisa Horvath, Susan J. Clark, PRIMe Consortium. Methylated glutathione s-transferase 1 (mGSTP1) as a potential plasma epigenetic marker of prognosis and response to chemotherapy in castrate-resistant prostate cancer (CRPC).

J Clin Oncol 32, 2014 (suppl 4; abstr 11)

Lisa Horvath, Hui-Ming Lin, Lesley Castillo, Kate Lynette Mahon, Karen Chiam, Brian Yong Lee, Quoc Nguyen, Wenjia Qu, Michael J. Boyer, Martin R. Stockler, Nick Pavlakis, Gavin M. Marx, Girish Mallesara Hiriyanna Gowda, Howard Gurney, Susan J. Clark, Alex Swarbrick, Roger J. Daly. Circulating microRNAs associated with docetaxel (DTX) resistant castration-resistant prostate cancer (CRPC).

J Clin Oncol 32. ASCO GU 2014

Lisa Horvath, Mark D. Chatfield, Michelle Lee-Ng, Hui-Ming Lin, Lesley Castillo, Samuel N. Breit, David A. Brown, Mark P. Molloy, Gavin M. Marx, Nick Pavlakis, Michael J. Boyer, Martin R. Stockler, Richard Wykes, Susan M. Henshall, Kate Lynette Mahon. The role of macrophages in docetaxel (DTX) resistance in castrate-resistant prostate cancer (CRPC).

J Clin Oncol 31, 2013 (suppl; abstr e22175) ASCO 2013


C. M. Won, H. Gurney, **G. Marx**, P. De Souza, M. I. Patel

Primary treatment of the prostate improves local palliation in men who ultimately develop castrate resistant prostate cancer.
*COSA/ANZUP November 2011*

*ASCO GU San Francisco 2008*

*COSA Melbourne 2006*

*ASCO Genitourinary Conference. San Francisco Jan 2006*

*Medical Oncology Group Meeting Hobart 2005*

Pavlakis N1, Mccowatt S1, Lewis C2, **Marx G**3, Abell F4, Della-Fiorentina S5, Boyce A6, Briggs P7, Horwood K8, Karapetis C9. Randomized Phase II study of first-line docetaxel (D)/gemcitabine (G) doublet chemotherapy versus fixed duration (3 cycles) sequential single agent chemotherapy (D then G) in Stage IIIB/IV non– small cell lung cancer (NSCLC) – Final Results. A study by the NSW and Australian Lung Cancer Trials Groups. 
*Submitted to WLCC Barcelona 2005*

*Submitted to ASCO 2005*

Pavlakis N, McCowatt S, Lewis C, **Marx G**, Abell F, Della Fiorentina S, Boyce A, Briggs P, Horwood K, Karapetis C. Randomized phase II comparison of first-line docetaxel (D)/gemcitabine (G) doublet chemotherapy versus fixed duration (3 cycles) sequential single agent chemotherapy (D then G) in stage IIIB/IV non–small cell lung cancer (NSCLC) – interim safety findings. A NSW Lung Cancer Trials Group initiated study. 
*ESMO Copenhagen 2004*
E Galani, G M Marx, A Strickland, S Rankin, R Mason, P G Harper. An evaluation of PET, EUS and CT scanning in the staging and response to chemotherapy of patients with oesophageal cancer and correlation with pathology at resection. Oral presentation. 12th Pan-hellenic congress of Clinical Oncology April 2004


An evaluation of PET, EUS and CT scanning in the staging and response of patients with oesophageal or gastro-oesophageal cancer and correlation with pathology at resection. E Galani, G M Marx, A Strickland, S Rankin, R Mason, J Meenan, A Poole, K F Chrystal, C B Steer, P G Harper. ASCO 2003


ASCO 2002

*Nuclear Medicine Communications* 2002; 23:408 (abstract P10)

*Abstract 17 MOG Sunshine Coast 2001*

*Abstract ASCO 1999*

*Poster MOG Meeting 1998*


*Poster COSA Melbourne 1999*

*Oral presentation COSA Melbourne 1999*